Portfolio, program, and project management in the pharmaceutical and biotechnology industries / edited by Pete Harpum

Mitwirkende(r):

Harpum, Pete [oth]

Resource type: Ressourcentyp: Buch (Online)Buch (Online)Sprache: Englisch Verlag: Hoboken : John Wiley & Sons, Incorporated, c2010Copyright-Datum: ©2010Auflage: Online-AusgBeschreibung: Online-Ressource (1 online resource (xvi, 331 p.)) : ill. (some col.)ISBN:

9781282550513
1282550519
9780470603772

Weitere Titel:

Pharmaceutical and biotechnology industries

Schlagwörter:

Andere physische Formen: 9780470049662 | 0470049669 | 1282547526 | Erscheint auch als: 9780470049662 Druck-AusgabeDDC-Klassifikation:

615.1068/4
615.10684

LOC-Klassifikation:

HD9665.5

NLM-Klassifikation:

2010 D-799
QV 736

Online-Ressourcen:

Zugang im Netz des KIT

Zusammenfassung: The EXPANSIVE, ALL-IN-ONE GUIDE to SUCCESSFUL PHARMACEUTICAL PROJECT MANAGEMENT To improve the ways they currently manage projects and programs, pharmaceutical and biotechnology companies need reliable stewardship to direct future strategies. Unlike other industry sectors, they have yet to fully embrace the effective integrated processes of Portfolio, Program, and Project Management, otherwise referred to as P3M, to position themselves favorably in meeting challenges unique to the drug development business. Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries illustrates how high-quality program and project management is crucial for drug companies to remain competitive, to deliver good returns to investors, and ultimately to bring novel personalized medicine to patients with: A combination of theoretical insights and pragmatic examples from professionals who are all working in the industry Case studies with very detailed, real-life examples of how the management of drug development is actually done Answers the pharmaceutical industry needs to streamline and make the drug development process more efficient The full spectrum of management processes needed from the operationalization of corporate strategy by portfolio management processes through to practical project control processes Carefully divided into three main sections to cover topics such as the impact of organizational size on P3M; planning and control; and reducing product safety risk, this informative reference is structured to align both novices and professionals in drug program management with success in the wake of emerging trends.Zusammenfassung: Intro -- Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries -- Contents -- Preface -- Acknowledgments -- About the Authors -- Part One The Life Science Industry Context for Portfolio, Program, and Project Management -- 1. A Review of Project Management in Life Science Industry Sectors -- 2. The Impact of Organizational Size on Drug Project Management -- 3. Drug Development in Biotechnology and How We Can Do It Better -- Part Two The Portfolio, Program, and Project Management Approaches and Processes -- 4. An Overview of the Organization and Processes of Portfolio, Program, and Project Management -- 5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market -- 6. Program Management in Drug Development -- 7. Project Control -- 8. Managing Uncertainty in Drug Projects -- 9. Managing Drug Safety Risk -- 10. Developing Program Strategy -- 11. Developing Products with "Added Value" -- Part Three Integrating the Processes -- 12. Integrated Business Processes to Support Cross-Functional Drug Development -- 13. Integrated Drug Development: From Cradle to Grave and from Lab to Market -- 14. The Development of P(3)M Capability in Drug Development Organizations -- 15. Implementing Portfolio, Program, and Project Management Best Practices in Drug Development Organizations -- Bibliography -- Index.PPN: PPN: 80730655XPackage identifier: Produktsigel: ZDB-26-MYL | ZDB-30-PAD | ZDB-30-PBE | ZDB-30-PQE

Exemplare ( 0 )

Dieser Titel hat keine Exemplare